tiprankstipranks
Trending News
More News >
IDEX Corporation (IEX)
NYSE:IEX
Advertisement

IDEX (IEX) AI Stock Analysis

Compare
347 Followers

Top Page

IEX

IDEX

(NYSE:IEX)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
$181.00
▲(8.38% Upside)
IDEX's strong financial performance and strategic initiatives are offset by bearish technical indicators and lowered guidance. The stock's valuation suggests it may be overvalued, and market uncertainties pose additional risks.
Positive Factors
Strong Cash Flow Management
Strong cash flow management ensures IDEX can sustain operations, invest in growth, and return capital to shareholders, supporting long-term stability.
Robust Balance Sheet
A strong balance sheet with low leverage enhances financial flexibility, enabling IDEX to navigate economic fluctuations and invest in strategic opportunities.
Successful Platform Optimization
Cost-saving initiatives improve operational efficiency and margins, providing a competitive edge and supporting long-term profitability.
Negative Factors
Lowered Financial Projections
Reduced financial projections signal potential revenue and profit challenges, impacting investor confidence and strategic planning.
Weakness in Key Segments
Weakness in key segments can hinder growth prospects and profitability, necessitating strategic adjustments to mitigate impact.
Order Volatility
Order volatility due to trade policies introduces revenue unpredictability, complicating supply chain and inventory management.

IDEX (IEX) vs. SPDR S&P 500 ETF (SPY)

IDEX Business Overview & Revenue Model

Company DescriptionIDEX Corporation, together with its subsidiaries, provides applied solutions worldwide. The company operates through three segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT segment designs, produces, and distributes positive displacement pumps, small volume provers, flow meters, injectors, and other fluid-handling pump modules and systems, as well as offers flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural, and energy industries. The HST segment designs, produces, and distributes precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, laboratory and commercial equipment, precision photonic solutions, and precision gear and peristaltic pump technologies. This segment serves food and beverage, pharmaceutical and biopharmaceutical, cosmetics, marine, chemical, wastewater and water treatment, life sciences, research, and defense markets. The FSDP segment designs, produces, and distributes firefighting pumps, valves and controls, rescue tools, lifting bags, and other components and systems for the fire and rescue industry; engineered stainless steel banding and clamping devices for various industrial and commercial applications; and precision equipment for dispensing, metering, and mixing colorants and paints used in retail and commercial businesses. IDEX Corporation was incorporated in 1987 and is headquartered in Northbrook, Illinois.
How the Company Makes MoneyIDEX generates revenue through multiple key streams, primarily by selling a diverse portfolio of products and solutions across its various business segments. The company earns money through direct sales of its engineered products, including pumps, valves, and flow measurement devices, which are utilized in critical processes across various industries. Additionally, IDEX benefits from recurring revenue through maintenance and service contracts associated with its products. Significant partnerships with other industrial firms and suppliers enhance its market reach and product offerings, allowing IDEX to capitalize on emerging market trends. Furthermore, IDEX invests in research and development, which helps maintain its competitive edge and drive innovation, further contributing to its revenue growth.

IDEX Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 28, 2025
Earnings Call Sentiment Neutral
The earnings call revealed strong Q2 financial performance and strategic capital deployment, but was overshadowed by reduced financial projections due to slower customer decision-making and geopolitical tensions. While there were notable achievements, such as better-than-expected Q2 results and successful M&A activity, these were balanced by significant challenges in key business areas and lowered guidance.
Q2-2025 Updates
Positive Updates
Better-than-Expected Q2 Results
IDEX's teams across all three segments delivered better-than-expected results in Q2 despite continued macro uncertainty.
Strong Q2 Financial Performance
Orders grew organically by 2%, and free cash flow increased by 25% year-over-year with a 94% conversion versus adjusted net income.
Successful Capital Deployment
The acquisition of Micro-LAM and strategic focus on tuck-in M&A to scale and expand critical capabilities in advantaged markets.
Continued M&A Activity
IDEX deployed $50 million to repurchase shares in Q2 and has $440 million remaining in its current authorization.
Successful Platform Optimization
Platform optimization and delayering initiatives delivered a combined $14 million in savings during Q2, in line with plans.
Negative Updates
Lowered Financial Projections for 2025
IDEX lowered its back half financial projections due to slower customer decision-making and geopolitical tensions.
Weakness in Semiconductor and Automotive
Continued softness in automotive, rescue tool, and parts of semiconductor businesses affected overall performance.
Order Volatility and Impact of Trade Policies
Unpredictable trade policy positioning led to oscillation in both small and larger order patterns, impacting Q2 results.
Challenges in Mott and MSS Businesses
Mott's growth slowed due to policy-driven demand uncertainties, and MSS group faced mix pressure impacting profitability.
Adjusted EPS Guidance Reduction
Adjusted EPS guidance for the year reduced to $7.85-$7.95 from $8.10-$8.45 previously, reflecting lower volumes and continued mix headwinds.
Company Guidance
During the IDEX Corporation's Second Quarter 2025 Earnings Conference Call, the company provided updated guidance for the fiscal year, adjusting their organic sales growth outlook to approximately 1%, down from the previous estimate of 1% to 3%. This revision is due to fluctuating order patterns and delays in customer decision-making, particularly impacting newer acquisitions in the Health and Science Technology (HST) segment. Despite these challenges, IDEX delivered an adjusted EBITDA margin of 27.4% in Q2, a decline of 40 basis points year-over-year, and achieved a free cash flow of $147 million, representing a 94% conversion of adjusted net income. The company also reported that their cost-saving initiatives remain on track, expecting $62 million in full-year savings from platform optimization and delayering actions. For the third quarter, IDEX anticipates 2% to 3% organic revenue growth and adjusted EPS of $1.90 to $1.95, reflecting ongoing market uncertainties and incremental tariff impacts, which are expected to be fully mitigated by price increases and supply chain efficiencies.

IDEX Financial Statement Overview

Summary
IDEX is financially sound with strong profitability, a solid balance sheet, and stable cash flows. The company maintains low leverage and efficient capital use, though there is a slight decline in operating margins.
Income Statement
85
Very Positive
IDEX demonstrates strong profitability with consistent gross and net profit margins. The TTM data shows a slight revenue growth, indicating stability in revenue generation. However, the EBIT and EBITDA margins have slightly decreased over the TTM, suggesting some pressure on operating efficiency.
Balance Sheet
90
Very Positive
The balance sheet is robust with a very low debt-to-equity ratio in the TTM, indicating minimal leverage risk. The return on equity is solid, reflecting efficient use of equity capital. The equity ratio is healthy, showing a strong capital structure.
Cash Flow
80
Positive
IDEX has a strong operating cash flow to net income ratio, indicating good cash generation relative to earnings. The free cash flow growth in the TTM is positive, although slightly lower than previous periods, suggesting stable cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.34B3.27B3.27B3.18B2.76B2.35B
Gross Profit1.45B1.52B1.62B1.59B1.36B1.16B
EBITDA805.70M859.40M964.10M909.80M720.50M604.60M
Net Income469.40M505.00M596.10M586.90M449.40M377.80M
Balance Sheet
Total Assets6.88B6.75B5.87B5.51B4.92B4.41B
Cash, Cash Equivalents and Short-Term Investments568.20M620.80M534.30M430.20M900.70M1.03B
Total Debt800.00K1.96B1.45B1.59B1.30B1.16B
Total Liabilities2.87B2.95B2.32B2.47B2.11B1.87B
Stockholders Equity4.01B3.79B3.54B3.04B2.80B2.54B
Cash Flow
Free Cash Flow587.00M603.00M626.80M489.40M492.60M517.70M
Operating Cash Flow645.30M668.10M716.70M557.40M565.30M569.30M
Investing Cash Flow-1.04B-1.01B-283.80M-917.20M-698.10M-172.60M
Financing Cash Flow234.90M465.90M-344.70M-37.80M-9.50M-42.60M

IDEX Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price167.00
Price Trends
50DMA
164.16
Positive
100DMA
172.53
Negative
200DMA
181.98
Negative
Market Momentum
MACD
-0.15
Negative
RSI
58.71
Neutral
STOCH
87.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IEX, the sentiment is Neutral. The current price of 167 is above the 20-day moving average (MA) of 162.03, above the 50-day MA of 164.16, and below the 200-day MA of 181.98, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 58.71 is Neutral, neither overbought nor oversold. The STOCH value of 87.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IEX.

IDEX Risk Analysis

IDEX disclosed 17 risk factors in its most recent earnings report. IDEX reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IDEX Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$14.13B28.4820.17%0.76%6.69%21.44%
75
Outperform
$13.12B29.3415.59%1.35%4.49%-3.33%
74
Outperform
$14.04B30.0519.62%1.27%0.75%-2.74%
73
Outperform
$12.57B26.9612.25%1.68%4.73%-19.15%
70
Outperform
$10.35B33.9518.23%0.50%3.01%27.13%
69
Neutral
$9.72B27.5214.59%9.69%54.29%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IEX
IDEX
167.00
-38.67
-18.80%
GNRC
Generac Holdings
165.67
-8.15
-4.69%
GGG
Graco
84.76
0.06
0.07%
ITT
ITT
181.16
33.52
22.70%
NDSN
Nordson
233.45
-15.63
-6.28%
CR
Crane Company
179.93
22.66
14.41%

IDEX Corporate Events

Executive/Board Changes
IDEX Announces CFO Resignation and Interim Appointment
Neutral
May 21, 2025

IDEX Corporation announced the resignation of its Senior Vice President and Chief Financial Officer, Abhishek Khandelwal, effective May 30, 2025. The company has appointed Akhil Mahendra as the interim CFO, who has been with IDEX for two years and previously worked at Rivian Automotive and Morgan Stanley. This transition is not due to any disagreements within the company, and an external search firm has been engaged to find a permanent replacement. The board has approved a restricted stock award for Mahendra, which will vest after three years, contingent on his continued service.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 30, 2025